JP2022009816A5 - - Google Patents

Download PDF

Info

Publication number
JP2022009816A5
JP2022009816A5 JP2021178682A JP2021178682A JP2022009816A5 JP 2022009816 A5 JP2022009816 A5 JP 2022009816A5 JP 2021178682 A JP2021178682 A JP 2021178682A JP 2021178682 A JP2021178682 A JP 2021178682A JP 2022009816 A5 JP2022009816 A5 JP 2022009816A5
Authority
JP
Japan
Prior art keywords
seq
cdr
binding
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021178682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022009816A (ja
Filing date
Publication date
Priority claimed from JP2021056457A external-priority patent/JP6971419B2/ja
Application filed filed Critical
Publication of JP2022009816A publication Critical patent/JP2022009816A/ja
Publication of JP2022009816A5 publication Critical patent/JP2022009816A5/ja
Pending legal-status Critical Current

Links

JP2021178682A 2020-03-31 2021-11-01 クローディン6を標的とする多重特異性抗原結合分子およびその使用 Pending JP2022009816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020062881 2020-03-31
JP2020062881 2020-03-31
JP2020073335 2020-04-16
JP2020073335 2020-04-16
JP2021056457A JP6971419B2 (ja) 2020-03-31 2021-03-30 クローディン6を標的とする多重特異性抗原結合分子およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021056457A Division JP6971419B2 (ja) 2020-03-31 2021-03-30 クローディン6を標的とする多重特異性抗原結合分子およびその使用

Publications (2)

Publication Number Publication Date
JP2022009816A JP2022009816A (ja) 2022-01-14
JP2022009816A5 true JP2022009816A5 (cg-RX-API-DMAC7.html) 2024-04-01

Family

ID=77928433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021056457A Active JP6971419B2 (ja) 2020-03-31 2021-03-30 クローディン6を標的とする多重特異性抗原結合分子およびその使用
JP2021178682A Pending JP2022009816A (ja) 2020-03-31 2021-11-01 クローディン6を標的とする多重特異性抗原結合分子およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021056457A Active JP6971419B2 (ja) 2020-03-31 2021-03-30 クローディン6を標的とする多重特異性抗原結合分子およびその使用

Country Status (18)

Country Link
US (1) US20230220066A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126956A4 (cg-RX-API-DMAC7.html)
JP (2) JP6971419B2 (cg-RX-API-DMAC7.html)
KR (2) KR102431028B1 (cg-RX-API-DMAC7.html)
CN (1) CN115397855A (cg-RX-API-DMAC7.html)
AU (1) AU2021247916A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017305A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174094A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002625A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015202A2 (cg-RX-API-DMAC7.html)
CR (2) CR20220540A (cg-RX-API-DMAC7.html)
IL (1) IL296478A (cg-RX-API-DMAC7.html)
MX (1) MX2022012092A (cg-RX-API-DMAC7.html)
PE (1) PE20221760A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552323A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104264TA (cg-RX-API-DMAC7.html)
TW (2) TWI900776B (cg-RX-API-DMAC7.html)
WO (1) WO2021200939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
JPWO2023053282A1 (cg-RX-API-DMAC7.html) * 2021-09-29 2023-04-06
MX2024008500A (es) * 2022-01-09 2024-08-26 I Mab Biopharma Co Ltd Construcciones multiespecíficas y usos de estas.
JP2025529310A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド 多特異性構築物およびその使用
CN119997975A (zh) * 2022-10-19 2025-05-13 安斯泰来制药株式会社 抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP3689911B1 (en) 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
US11541076B2 (en) * 2017-01-13 2023-01-03 Celdara Medical, Llc Chimeric antigen receptors targeting TIM-1
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP2021510064A (ja) * 2018-01-05 2021-04-15 中外製薬株式会社 細胞傷害誘導治療剤
JP2022501325A (ja) * 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
JP7359864B2 (ja) * 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用

Similar Documents

Publication Publication Date Title
CN107922486B (zh) 异源二聚体多特异性抗体形式
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
US12098203B2 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
JP7031810B2 (ja) 抗pd-1/抗her2天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法
RU2015144098A (ru) Четырехвалентные биспецифические антитела
WO2020186974A1 (zh) 一种双特异性抗体及其制备方法与应用
RS62151B1 (sr) Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2021175391A5 (cg-RX-API-DMAC7.html)
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
WO2022206900A1 (zh) 抗人血清白蛋白(hsa)的纳米抗体及其应用
TW201934582A (zh) 抗pd-1/抗her2天然抗體結構樣異源二聚體形式雙特異抗體及其製備
US20180371088A1 (en) TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
WO2022267936A1 (zh) 特异性结合糖基化ceacam5的抗体
CN111378044A (zh) 抗体融合蛋白、制备方法及其应用
JP2024509910A5 (cg-RX-API-DMAC7.html)
CN116964084A (zh) 双特异性抗体
JP2025504909A5 (cg-RX-API-DMAC7.html)
JP2024516098A5 (cg-RX-API-DMAC7.html)
WO2023072217A1 (en) Fusion proteins targeting cd3 and cd47
CN115433277A (zh) 抗cd38兔重组单克隆抗体的制备及应用
WO2024061224A1 (zh) 抗her2抗体及其用途
CN111378045A (zh) 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
JP2024515301A5 (cg-RX-API-DMAC7.html)
JP2025528101A (ja) 多重特異性ポリペプチド複合体